Contribute Try STAT+ Today

A five-year bull run in biotech has made scientists into millionaires, booked bonuses for bankers, and put venture capitalists into increasingly fancy cars. But in an industry prone to booms and busts, insiders with long memories aren’t getting too comfortable.

“I’m seeing a lot of investors making a lot of assumptions that may be accurate, but these assumptions are now becoming the consensus, and if anything goes wrong, there’s a long way down,” said Josh Schimmer, a biotech analyst at Evercore ISI.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
    • There have been ridiculous run ups for and valuations for companies like BGNE, ATRA, NKTR and countless others that are no where near approved/marketable products. In earlier times, this would have been considered a bubble.

Comments are closed.